entertainment -WSS

entertainment

author：entertainment 2025-09-28 16:35:09 - browse：57

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： There's an unseen cost to disruptive road

WSS

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

Immunocompromised patients offer clues on chronic Covid

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

Future doctors need a strong humanities education

entertainment

entertainment

hotspot

Walensky prepares to leave CDC — and Congress — behind

Microsoft launches AI tool for clinical documentation through Epic

Medicare details structure of new drug price negotiation program

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

Medical leaders decry Supreme Court decision on affirmative action

'Of course' Trump lost the 2020 election, DeSantis says after years of hedging

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Dana Farber says 6 studies to be retracted and 31 corrected

Medical records are filled with copy

The inclusion problem at the heart of rehabilitation research

hotspot

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Printout prescription drug information shouldn’t go digital

Trump attorney outlines possible Jan. 6 legal defenses, but some experts are skeptical

Discs beat pads, tampons for heavy menstrual flow, new study shows

Medicare drug price lawsuits could be good politics for Biden

Former Georgia lieutenant governor says he received grand jury subpoena

focus

leisure time

leisure time

entertainment